Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 675,000 Shares of Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi acquired 675,000 shares of the firm’s stock in a transaction on Tuesday, March 25th. The stock was bought at an average price of $0.69 per share, with a total value of $465,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,999,296 shares in the company, valued at approximately $1,379,514.24. This represents a 50.97 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, March 12th, Krishna Vaddi purchased 47,500 shares of Prelude Therapeutics stock. The stock was bought at an average cost of $0.71 per share, with a total value of $33,725.00.
• On Monday, December 30th, Krishna Vaddi acquired 10,000 shares of Prelude Therapeutics stock. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $12,000.00.

Prelude Therapeutics Stock Performance

Shares of PRLD opened at $0.68 on Friday. The firm’s 50-day simple moving average is $0.90 and its two-hundred day simple moving average is $1.35. Prelude Therapeutics Incorporated has a fifty-two week low of $0.63 and a fifty-two week high of $6.80. The stock has a market cap of $37.60 million, a PE ratio of -0.38 and a beta of 1.43.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.11. The company had revenue of $4.00 million for the quarter. Equities research analysts predict that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Hedge Funds Weigh In On Prelude Therapeutics

A number of hedge funds have recently bought and sold shares of PRLD. Boxer Capital Management LLC bought a new stake in Prelude Therapeutics during the 4th quarter valued at about $2,178,000. Jacobs Levy Equity Management Inc. increased its position in shares of Prelude Therapeutics by 280.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 666,574 shares of the company’s stock valued at $850,000 after acquiring an additional 491,595 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Prelude Therapeutics by 222.2% during the fourth quarter. Renaissance Technologies LLC now owns 634,500 shares of the company’s stock valued at $809,000 after acquiring an additional 437,600 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Prelude Therapeutics by 5.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 549,530 shares of the company’s stock valued at $1,138,000 after acquiring an additional 27,155 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Prelude Therapeutics by 188.2% during the 4th quarter. Millennium Management LLC now owns 462,555 shares of the company’s stock valued at $590,000 after purchasing an additional 302,031 shares during the last quarter. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.